Showing results (751-760 of 782) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|April 1, 2021
HIV testing approaches to reach the first UNAIDS 95% target in sub-Saharan AfricaGabriel Chamie, Sue Napierala, Kawango Agot, et al.
The Lancet. HIV|August 9, 2025
The clinical and economic impact of genotypic resistance testing for people diagnosed with persistent virological non-suppression on tenofovir-lamivudine-dolutegravir in South Africa: a modelling studyEmily P Hyle, Linda-Gail Bekker, Suzanne M McCluskey, et al.
The Lancet. HIV|October 31, 2025
Safety outcomes among infants whose mothers used the dapivirine vaginal ring or oral PrEP during pregnancy (MTN-042/DELIVER): a randomised phase 3b studyLee Fairlie, Daniel W Szydlo, Ashley Mayo, et al.
The Lancet. HIV|June 20, 2025
Do we need routine integrase resistance testing before starting antiretroviral therapy?Rami Kantor, Alice K Pau, Michael J Kozal, et al.
The Lancet. HIV|February 28, 2024
Retiring the term AIDS for more descriptive languageIsaac Núñez, Alicia Piñeirúa-Menéndez, Sergio Iván Valdés-Ferrer
The Lancet. HIV|March 2, 2024
Health equity for Black sexually minoritised men through status-neutral HIV careJade Pagkas-Bather, Darnell N Motley, John A Schneider
The Lancet. HIV|April 7, 2024
Voucher incentives to improve viral suppression among HIV-positive people who inject drugs and men who have sex with men in India: a cluster randomised trialSunil S Solomon, Allison M McFall, Aylur K Srikrishnan, et al.
The Lancet. HIV|March 8, 2024
Uncovering HIV and malaria interactions: the latest evidence and knowledge gapsAntía Figueroa-Romero, Anna Saura-Lázaro, Sheila Fernández-Luis, et al.
The Lancet. HIV|March 11, 2024
Progress towards the UNAIDS 95-95-95 targets in the Fifth Botswana AIDS Impact Survey (BAIS V 2021): a nationally representative surveyMadisa Mine, Kristen A Stafford, Rebecca L Laws, et al.
The Lancet. HIV|March 27, 2024
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding studyAditya H Gaur, Edmund V Capparelli, Katherine Calabrese, et al.
Pageof 79